IHL says it had a positive pre-Investigational New Drug Application (pre-IND) meeting with the US Food and Drug Administration (FDA) on its IHL-216A drug, which is a combination of CBD and isoflurane (ISO) that is being developed for treatment of traumatic brain injury and concussion (TBI).
“Feedback from the FDA in the pre-IND meeting indicated that the agency is highly interested in the development of IHL-216A for treatment of traumatic brain injury,” chief scientific officer Dr Mark Bleackley said.
“Their responses covered all aspects of the proposed development and engaged a range of disciplinary experts that provided useful insight on all aspects of our development plan.
“The FDA has provided essential advice on inhaled drug development that will guide the most efficient development of IHL-216A.”
Not meaning to cross promote just to highlight background work ongoing with FDA...............happy days
Ann: TGA advertising infringement notices, page-20
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
